Cargando…

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease

Continuous infusion of levodopa or apomorphine provide constant dopaminergic stimulations are good alternatives to deep brain stimulation to control motor fluctuations in patients with advanced Parkinson’s disease (PD). Apomorphine provides motor benefit similar to dopamine, but its long-term use is...

Descripción completa

Detalles Bibliográficos
Autor principal:	Antonini, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Movement Disorder Society 2009
Materias:	Invited Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027699/ https://www.ncbi.nlm.nih.gov/pubmed/24868344 http://dx.doi.org/10.14802/jmd.09002

Ejemplares similares

Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease
por: Jenner, P., et al.
Publicado: (2023)

Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review
por: Gaire, Suman, et al.
Publicado: (2021)

Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson's Disease
por: Nishijima, Haruo, et al.
Publicado: (2018)

Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson’s disease
por: Hagell, Peter, et al.
Publicado: (2020)

Long-term effect of apomorphine infusion in advanced Parkinson’s disease: a real-life study
por: Meira, Bruna, et al.
Publicado: (2021)

Infusion Therapies in the Treatment of Parkinson’s Disease
por: van Laar, Teus, et al.
Publicado: (2023)

Necrotic Ulcers Secondary to Apomorphine Infusion
por: Llamas-Osorio, Yudy, et al.
Publicado: (2021)

Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson’s disease: A prospective study of 22 patients
por: Fernández-Pajarín, Gustavo, et al.
Publicado: (2021)

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Poewe, Werner, et al.
Publicado: (2010)

Apomorphine in Parkinson's Disease—The Questions Raised
por: Dhamija, Rajinder K., et al.
Publicado: (2020)

Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson’s disease on levodopa/carbidopa intestinal gel infusion
por: Garrì, Federica, et al.
Publicado: (2022)

Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review
por: Tsunemi, Taiji, et al.
Publicado: (2021)

Safety and tolerability of long-term apomorphine infusion in advanced Parkinson's disease: an Indian multi-center (APO-IND) experience
por: Metta, Vinod, et al.
Publicado: (2023)

Current and novel infusion therapies for patients with Parkinson's disease
por: Antonini, Angelo, et al.
Publicado: (2023)

Practical use of apomorphine infusion in Parkinson’s disease: lessons from the TOLEDO study and clinical experience
por: Henriksen, Tove, et al.
Publicado: (2023)

Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: the APOKADO study
por: Zagnoli, Fabien, et al.
Publicado: (2023)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
por: Antonini, Angelo, et al.
Publicado: (2016)

Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa
por: Zadikoff, Cindy, et al.
Publicado: (2020)

Correction to: Long-term safety, discontinuation and mortality in an Italian cohort with advanced Parkinson’s disease on levodopa/carbidopa intestinal gel infusion
por: Garrì, Federica, et al.
Publicado: (2022)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson's disease
por: Diaconu, Ştefania, et al.
Publicado: (2023)

Continuous subcutaneous apomorphine infusion allowing awake deep brain stimulation in a Parkinson’s disease patient
por: Spagnolo, Francesca, et al.
Publicado: (2021)

Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations
por: Carbone, Federico, et al.
Publicado: (2019)

Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance
por: Nyholm, Dag, et al.
Publicado: (2022)

Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson’s disease
por: Agbo, Felix, et al.
Publicado: (2021)

Night‐Time Apomorphine Infusion: Who Are the Best Candidates?
por: Cochen De Cock, Valérie, et al.
Publicado: (2023)

Beyond the Dopaminergic System: Lessons Learned from levodopa Resistant Symptoms in Parkinson's Disease
por: Antonini, Angelo, et al.
Publicado: (2023)

Continuous levodopa for advanced Parkinson’s disease
por: Lundqvist, Christofer
Publicado: (2007)

Task Specific Tremor in Parkinson’s Disease Responds to Apomorphine
por: Ondo, William G., et al.
Publicado: (2023)

Apomorphine Monotherapy for Parkinson’s Disease: A Neglected Option?
por: Desjardins, Clément, et al.
Publicado: (2023)

Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
por: Borkar, Nrupa, et al.
Publicado: (2018)

Levodopa–carbidopa intrajejunal infusion in Parkinson’s disease: untangling the role of age
por: Morgante, Francesca, et al.
Publicado: (2020)

Population pharmacokinetics of levodopa gel infusion in Parkinson’s disease: effects of entacapone infusion and genetic polymorphism
por: Senek, M., et al.
Publicado: (2020)

Combined and Sequential Treatment with Deep Brain Stimulation and Continuous Intrajejunal Levodopa Infusion for Parkinson’s Disease
por: van Poppelen, Daniël, et al.
Publicado: (2021)

The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review
por: Antonini, Angelo, et al.
Publicado: (2021)

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Apomorphine
Publicado: (1900)

Apomorphine
Publicado: (1888)

Apomorphine effects on the hippocampus
por: Arroyo-García, Luis Enrique, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ehibe7l9jrf4qpbnouqjndhrkr